GB2514285A - Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors - Google Patents

Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors Download PDF

Info

Publication number
GB2514285A
GB2514285A GB1414378.8A GB201414378A GB2514285A GB 2514285 A GB2514285 A GB 2514285A GB 201414378 A GB201414378 A GB 201414378A GB 2514285 A GB2514285 A GB 2514285A
Authority
GB
United Kingdom
Prior art keywords
intermediates
tyrosine kinase
kinase inhibitors
novel process
related tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB1414378.8A
Other versions
GB2514285B (en
GB201414378D0 (en
Inventor
Viesturs Lusis
Svetlana Stupnikova
Dzintra Muceniece
Armands Zandersons
Deniss Laipnieks
Edvards Lavrinovics
Indra Jonane-Osa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grindeks JSC
Original Assignee
Grindeks JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks JSC filed Critical Grindeks JSC
Publication of GB201414378D0 publication Critical patent/GB201414378D0/en
Publication of GB2514285A publication Critical patent/GB2514285A/en
Application granted granted Critical
Publication of GB2514285B publication Critical patent/GB2514285B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

4-Oxo-2-phenylaminopyrimidine derivatives as intermediates for synth of tyrosine kinase inhibitors, in particular imatinib and nilotinib.
GB1414378.8A 2012-02-13 2013-02-12 Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors Expired - Fee Related GB2514285B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12155116 2012-02-13
EP12155117 2012-02-13
EP12198885 2012-12-21
PCT/EP2013/052790 WO2013120852A1 (en) 2012-02-13 2013-02-12 Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
GB201414378D0 GB201414378D0 (en) 2014-09-24
GB2514285A true GB2514285A (en) 2014-11-19
GB2514285B GB2514285B (en) 2018-07-18

Family

ID=47757568

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1414378.8A Expired - Fee Related GB2514285B (en) 2012-02-13 2013-02-12 Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors

Country Status (2)

Country Link
GB (1) GB2514285B (en)
WO (1) WO2013120852A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105985293B (en) * 2015-03-04 2018-04-03 埃斯特维华义制药有限公司 The preparation method of AMN107 intermediate
US10000470B1 (en) * 2015-05-26 2018-06-19 Asymchem Laboratories (Tianjin) Co., Ltd Method for preparing nilotinib
US11091466B2 (en) 2017-03-17 2021-08-17 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of PCSK9

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070350A2 (en) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
WO2008135980A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Imatinib production process
WO2009065910A2 (en) * 2007-11-21 2009-05-28 ECZACIBASI-ZENTIVA Kimyasal Ürünler Sanayi ve Ticaret A.S. Novel acid addition salts of imatinib and formulations comprising the same
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US7507821B2 (en) 2004-12-30 2009-03-24 Chemagis Ltd. Process for preparing Imatinib
SA06270147B1 (en) 2005-06-09 2009-12-22 نوفارتيس ايه جي Process for the Synthesis Of 5-(methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
KR101420892B1 (en) 2006-11-16 2014-07-17 에프.아이.에스. 파브리카 이탈리아나 신테티치 에스.피.에이. Process for the preparation of Imatinib and intermediates thereof
CN100451015C (en) 2007-02-14 2009-01-14 杭州盛美医药科技开发有限公司 Preparing method of imatinib
RU2329260C1 (en) 2007-02-20 2008-07-20 Юрий Иосифович Копырин Method of obtaining 2-anilinopyrimidines or their salts (options)
CN101497601B (en) 2008-01-29 2012-11-07 福建南方制药股份有限公司 Process for synthesizing imatinib
PL215042B1 (en) 2008-08-01 2013-10-31 Temapharm Spolka Z Ograniczona Odpowiedzialnoscia Method of imatinib manufacturing
US8912325B2 (en) 2011-03-31 2014-12-16 Ind-Swift Laboratories Limited Process for preparation of imatinib and its mesylate salt

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070350A2 (en) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
WO2008135980A1 (en) * 2007-05-02 2008-11-13 Chemagis Ltd. Imatinib production process
WO2009065910A2 (en) * 2007-11-21 2009-05-28 ECZACIBASI-ZENTIVA Kimyasal Ürünler Sanayi ve Ticaret A.S. Novel acid addition salts of imatinib and formulations comprising the same
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FU-AN KANG ET AL: "Pd-Catalyzed Direct Arylation of Tautomerizable Heterocycles with Aryl Boronic Acids via C-OH Bond Activation Using Phosphonium Salts", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 130, no. 34, 1 August 2008 (2008-08-01), pages 11300-11302, XP055023170, ISSN: 0002-7863, DOI: 10. *
WEI-SHENG HUANG ET AL: "An Efficient Synthesis of Nilotinib (AMN107)", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE, no. 14, 1 January 2007 (2007-01-01), pages 2121-2124, XP002572746, ISSN: 0039-7881, DOI: 10.1055/S-2007-983754 [retrieved on 2007-07-03] *
ZIMMERMANN J ET AL: "Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 6, no. 11, 4 June 1996 (1996-06-04), pages 1221-1226, XP004134858, *

Also Published As

Publication number Publication date
GB2514285B (en) 2018-07-18
GB201414378D0 (en) 2014-09-24
WO2013120852A4 (en) 2013-10-10
WO2013120852A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
HRP20181429T8 (en) Novel benzimidazole derivatives as kinase inhibitors
HK1213883A1 (en) Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
HK1211293A1 (en) Brutons tyrosine kinase inhibitors
HK1212689A1 (en) Inhibitors of brutons tyrosine kinase
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
SI2710005T1 (en) Tyrosine kinase inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MX341456B (en) Amino-quinolines as kinase inhibitors.
HK1210779A1 (en) Inhibitors of brutons tyrosine kinase
HK1210461A1 (en) Inhibitors of brutons tyrosine kinase
EA201270280A1 (en) Pyrimidine Compounds as Inhibitors in the Treatment of Tuberculosis
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
HK1215855A1 (en) Inhibitors of brutons tyrosine kinase
GEP201706626B (en) Synthesis of (s)-nifuratel
MY167584A (en) Method for producing ethanol
HK1210616A1 (en) Process for the preparation of c-fms kinase inhibitors c-fms
AU2016204389A1 (en) Kinase inhibitors for the treatment of cancer
EP2731439A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB2514285A (en) Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
IN2013MU01113A (en)
UA110626C2 (en) Process for preparing pan-cdk inhibitors of the formula (i), and also to intermediates in the preparation
PH12014501760B1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
EP3006428A4 (en) Novel maleic acid derivative, production method for same and anti-cancer composition comprising same

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20210212